These results corroborate the tumour-promoting effects of NCBP2 observed in our functional studies and provide important clues to how downstream NCBP2 signalling may lead to a more aggressive tumour abetting phenotype and how such signalling may be effectively targeted for therapeutic benefit. This evidence concerns the gene NCBP2 and neoplasm.